Group 1 - Royalty Pharma appointed Vlad Coric, M.D. to its Board of Directors, effective immediately [1][2] - Vlad Coric is the Chairman and CEO of Biohaven, a biopharmaceutical company with a focus on neuroscience, immunology, and oncology [1][2] - Coric's leadership at Biohaven included the FDA approval and launch of Nurtec ODT for migraine treatment and the filing of an NDA for zavegepant [2][3] - Under Coric's leadership, Biohaven grew significantly and was sold to Pfizer for approximately $13 billion in May 2022 [2] Group 2 - Coric has over 20 years of experience in drug discovery and clinical development, with expertise in various therapeutic areas [3] - His educational background includes a medical degree from Wake Forest University and a Bachelor of Science degree from the University of Connecticut [3] - Royalty Pharma is the largest buyer of biopharmaceutical royalties and funds innovation in the biopharmaceutical industry [4] - The company collaborates with a range of entities, from academic institutions to leading global pharmaceutical companies, and has a portfolio of royalties on over 35 commercial products [4]

Core Insights - Royalty Pharma plc has appointed Vlad Coric, M.D. to its Board of Directors, effective immediately, enhancing its leadership team with his extensive biopharmaceutical experience [1][2]. Group 1: Appointment and Leadership - Vlad Coric is the Chairman and CEO of Biohaven, a biopharmaceutical company focused on neuroscience, immunology, and oncology [1][2]. - Pablo Legorreta, CEO of Royalty Pharma, expressed excitement about Coric's appointment, highlighting his entrepreneurial approach and leadership skills as valuable assets [2]. - Coric has notable experience in royalty funding, having completed multiple transactions with Royalty Pharma during his time at Biohaven [2]. Group 2: Achievements and Experience - Under Coric's leadership, Biohaven achieved FDA approval and launched Nurtec ODT for migraine treatment, and filed an NDA for zavegepant, the first intranasal CGRP antagonist for ultra-rapid migraine relief [2]. - Coric oversaw Biohaven's growth from its founding to its sale to Pfizer in May 2022 for approximately $13 billion [2]. - He has over 20 years of experience in drug discovery and clinical development, with expertise across various therapeutic areas including neurology, psychiatry, and oncology [3]. Group 3: Company Overview - Royalty Pharma, founded in 1996, is the largest buyer of biopharmaceutical royalties and a leading funder of innovation in the biopharmaceutical industry [4]. - The company collaborates with a range of innovators, from academic institutions to leading global pharmaceutical companies, and has a portfolio of royalties based on top-line sales of leading therapies [4]. - Royalty Pharma's portfolio includes royalties on over 35 commercial products and 15 development-stage candidates, indicating a strong position in the biopharmaceutical market [4].

NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will host an Investor Day in New York City on Thursday, September 11, 2025, starting at 8:30 a.m. ET. Royalty Pharma senior executives will provide an update on the company’s plans to drive shareholder value creation through leveraging its unique business model and capabilities in the large and growing market for funding biopharma innovation. The meeting will include live question and answer sessions. Addi ...

NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at TD Cowen’s 45th Annual Health Care Conference on March 4, 2025 at 2:30 p.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/events/. The webcast will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties an ...

Following our recent update on Royalty Pharma plc (NASDAQ: RPRX ) - Key Strategic Updates To Be Priced In , we are back to comment on the company's quarterly results. Since our strong buy recommendation released in earlyBuy-side hedge professionals conducting fundamental, income oriented, long term analysis across sectors globally in developed markets. Please shoot us a message or leave a comment to discuss ideas.DISCLOSURE: All of our articles are a matter of opinion, informed as they might be, and must be ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to __________ 110 East 59 Street th New York, New York 10022 (Address of principal executive offices and Zip Code) (212) 883-0200 (Registrant's telephone ...

NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it has entered into an agreement with Biogen to provide research and development (R&D) funding of up to $250 million for litifilimab, a first-in-class investigational drug candidate in Phase 3 with demonstrated proof-of-concept in both systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). "We are excited to collaborate with Biogen on litifilimab," said Pablo Legorreta, Royalty Pharma's fou ...

Royalty Pharma to provide R&D investment of up to $250 million for Biogen’s litifilimab, a potential first-in-class biologic in Phase 3 development for the treatment of lupusNEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has entered into an agreement with Biogen to provide research and development (R&D) funding of up to $250 million for litifilimab, a first-in-class investigational drug candidate in Phase 3 with demonstrated proof-of-concept in both sys ...

Strong Royalty Receipts growth; Portfolio Receipts growth impacted by a high base of comparison Capital Deployment of $2.8 billion in 2024 with royalties on eight new therapies added to the portfolio Exciting new product launches expected across the royalty portfolio in 2025 • Royalty Pharma to benefit in 2025 from new product launches, including Servier's Voranigo, Bristol Myers Squibb's Cobenfy, Ascendis' Yorvipath, Syndax and Incyte's Niktimvo and Geron's Rytelo. Financial guidance for full year 2025 (ex ...

Financial Data and Key Metrics Changes - Royalty Pharma reported Portfolio Receipts of $2.8 billion for 2024, representing a growth of 13% compared to the previous year, significantly exceeding the initial guidance of 5% to 9% [9][10][39] - The company expects Portfolio Receipts for 2025 to be in the range of $2.9 billion to $3.05 billion, indicating a growth of approximately 4% to 9% [49][50] Business Line Data and Key Metrics Changes - The company added royalties on AD therapy, including four development-stage therapies, and saw positive news across its portfolio with several FDA approvals [11][12] - Synthetic royalty transactions reached a record of $925 million in 2024, more than doubling since 2020, highlighting the growing demand for this funding modality [26][30] Market Data and Key Metrics Changes - Royalty Pharma reviewed over 440 potential royalty transactions in 2024, a 10% increase from the previous year, indicating strong market demand for royalty financing [21][58] - The company maintains a diversified portfolio with more than 35 approved products and 14 development-stage therapies, including 15 blockbuster therapies [15][16] Company Strategy and Development Direction - The company announced a transformative acquisition of its external manager to become an integrated company, expected to close in Q2 2025, which is anticipated to enhance shareholder value and operational efficiency [13][14][17] - Royalty Pharma's capital allocation framework will scale buybacks based on the discount of share price to intrinsic value, with a new $3 billion share repurchase plan authorized [12][46] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver strong financial performance in 2025, driven by a diversified portfolio and strategic capital deployment [56][59] - The company is closely monitoring the impact of new healthcare policies and does not foresee significant changes in taxation affecting its business [62][68] Other Important Information - The company generated over $0.5 billion in cash by monetizing the MorphoSys development funding bonds, which will be redeployed for further investments [13][41] - Operating and professional costs are expected to be approximately 10% of portfolio receipts in 2025, with significant savings anticipated post-internalization [52][120] Q&A Session Summary Question: Guidance details and assumptions for 2025 - Management has not provided specific product-by-product guidance but expects key contributors like the CF franchise to remain significant [63][64] Question: Risks from new administration policies - Management is monitoring the situation closely and does not foresee any major impacts on taxation [68] Question: Returns on synthetic royalties compared to traditional structures - Management indicated that synthetic royalties have shown strong returns and are increasingly embraced by the sector as an alternative funding method [75][76] Question: Timing of arbitration process regarding Vertex royalty - Management stated that arbitration is typically quicker than court processes, but no specific timing can be provided at this moment [78] Question: Historical performance versus guidance - Management acknowledged that historically, the company has outperformed guidance and expressed confidence in the current portfolio's momentum [80][84] Question: Screening process for transactions - The company maintains a disciplined approach, focusing on product quality, clinical data, and commercial potential, which leads to a selective transaction process [86][88]